Evaluation of lapatinib and topotecan combination therapy: Tissue culture, murine xenograft, and phase i clinical trial data

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7900-7908

  Molina, Julian R ^a,d   Kaufmann, Scott H ^a,b   Reid, Joel M ^a   Rubin, Stephen D ^c   Gálvez Peralta, Marina ^a   Friedman, Robert ^c   Flatten, Karen S ^a   Koch, Kevin M ^c   Gilmer, Tona M ^c   Mullin, Robert J ^c   Jewell, Roxanne C ^c   Felten, Sara J ^a   Mandrekar, Sumithra ^a   Adjei, Alex A ^a   Erlichman, Charles ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TOPOTECAN; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TISSUE CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; VOMITING; ANIMAL; BREAST TUMOR; DRUG SCREENING; MIDDLE AGED; NEOPLASM; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59449088659     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0415     Document Type: Article

References (45)

1. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor recep- tor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol CancerTher 2001;1:85-94.
2. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov 2007;6:431 -2.
3. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
4. Rusnak DW, Alligood KJ, Mullin RJ, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-94.
5. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006;11: 1047-57.
6. Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 2007;5:314-23.
7. Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007;7: 1183-92.
8. Sparreboom A, Zamboni WC. Topoisomerase I-targeting drugs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. 4th ed. Lippin-cott Williams&Wilkins; 2006.p.371 -413.
9. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
10. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
11. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22: 3205-12.
12. Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Huntingt) 2006;20:15-25.
13. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40Suppl:S3-8.
14. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
15. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
16. Szakacs G, Paterson JK, LudwigJA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
17. ChenAY, Yu C, PotmesilM, Wall ME, WaniMC, Liu LF. Camptothecin overcomes mdrl-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51:6039-44.
18. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect of P-glycopro- tein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992;52:2268-78.
19. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res1999;59:4559-63.
20. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
21. Erlichman C, Boerner SA, Hallgren CG, et al. The HER tyrosine kinaseinhibitor CI1033 enhances cytotoxicity of7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61:739-48.
22. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7:935-41.
23. Zhuang Y, Fraga CH, Hubbard KE, et al. Topote- can central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 2006;66: 11305-13.
24. deVries NA, Zhao J, Kroon E, BuckleT, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007;13:6440-9.
25. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
26. Maliepaard M, Scheffer GL, Faneyte IF, et al. Sub-cellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
27. Diestsra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABC tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-9.
28. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002;3:1652-9.
29. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? PharmacolTher 2007;113:429-41.
30. Nakamura Y, Oka M, Soda H, et al. Gefitinib ("Iressa," ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541 -6.
31. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66: 4802-7.
32. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in lapatinib (Tykerb, GW572016) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701.
33. Riordan JR, Deuchars K, Kartner N, Alon N,Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316: 817-9.
34. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277:44236-43.
35. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993;85:1637-43.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
37. Hsieh S, TobienT, Koch K, Dunn J. Increasing throughput of parallel on-line extraction liquid chro- matography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 2004;18:285-92.
38. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
39. Lev DC, Kim LS, Melnikova V, RuizM, Ananthaswamy HN, Price JE. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br J Cancer 2004;91:795-802.
40. Olsson P, Gedda L, Goike H, et al. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression. Anticancer Drug Des 1998;13:279-89.
41. Gilmer TM, CableL, Alligood K, et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 2008;68:571 -9.
42. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170-1.
43. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
44. Masumoto S,Yoshida K, Ishiguro N. Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylami- nomethyl-10-hydroxy-camptothecin hydrochloride]. J Pharmacol Exp Ther 2007;322:1246-52.
45. Huls M, Brown CDA,Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2007;10:1038-44.